Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics (Nasdaq: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development.

The company’s CEO, Martin Lehr, scientific lead Dr Eric Butz and research lead Dr Joseph Rucker will discuss Context’s CLDN6 x CD3 bispecific antibody’s American Association for Cancer Research 2023 presentation and provide preclinical program updates on this potential treatment for multiple solid tumors including ovarian, lung and testicular cancers.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free